Journal
CELLS
Volume 12, Issue 6, Pages -Publisher
MDPI
DOI: 10.3390/cells12060935
Keywords
cancer screening; multi-cancer early detection; MCED; liquid biopsy; biomarkers
Categories
Ask authors/readers for more resources
Cancer is a major cause of death worldwide due to late detection and limited therapeutic options. Existing screening procedures for most cancers have drawbacks, leading to low patient compliance and increased costs. Multi-cancer early detection (MCED) tests, combining molecular analysis and artificial intelligence, have emerged as a promising tool for early cancer detection.
Cancer remains a leading cause of death worldwide, partly owing to late detection which entails limited and often ineffective therapeutic options. Most cancers lack validated screening procedures, and the ones available disclose several drawbacks, leading to low patient compliance and unnecessary workups, adding up the costs to healthcare systems. Hence, there is a great need for innovative, accurate, and minimally invasive tools for early cancer detection. In recent years, multi-cancer early detection (MCED) tests emerged as a promising screening tool, combining molecular analysis of tumor-related markers present in body fluids with artificial intelligence to simultaneously detect a variety of cancers and further discriminate the underlying cancer type. Herein, we aim to provide a highlight of the variety of strategies currently under development concerning MCED, as well as the major factors which are preventing clinical implementation. Although MCED tests depict great potential for clinical application, large-scale clinical validation studies are still lacking.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available